Eur J Nucl Med Mol Imaging 2003;30:510-8. 11. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.. Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment. Abstract. Purpose: Bronchial and gastroenteropancreatic neuroendocrine tumors (NET) are slow-growing tumors, which frequently express somatostatin receptors on their cell membranes. These receptors are targets for therapy with Lutetium-177-labeled somatostatin analogues. We have treated over 1,200 patients with peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate.
Meltingpot Kooij
Gallium 68 (68Ga) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-octreotate (DOTATATE, GaTate) positron emission tomography (PET)/computed tomography (CT) is an imaging technique for detecting and characterizing neuroendocrine tumors (NETs). GaTate, a somatostatin analog, has recently been accorded orphan drug status by the U.S. Food and Drug Administration, thereby. Conclusion. 99m Tc-demogastrin 2 scintigraphy appeared most promising as a diagnostic tool in patients with MTC. Further studies are required to evaluate its value in patient management. Direct comparisons of the compounds studied strongly suggests that 111 In-DOTA-CCK and 111 In-DOTA-MG11 have less potential as imaging agents than 99m Tc-demogastrin 2. . These DOTA-linked compounds are. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003; 30 (1):9-15. doi: 10.1007/s00259-002-0982-3. [Google Scholar] Eur J Nucl Med Mol Imaging.. E P Krenning, J J M Teunissen, P P M Kooij, A L H van Gameren, W H Bakker, D J Kwekkeboom. Affiliation 1 Department of Nuclear Medicine, Erasmus MC Rotterdam, The Netherlands.
[email protected]; PMID: 16847654 DOI: 10.1007/s00259-006-0172-9 Abstract Purpose:.
Family Kooij 1of 2 The site of the famous Kooij Family Chr… Flickr
The mean absorbed kidney dose in 228 patients was 20.1 ± 4.9 Gy. Conclusion: Nephrotoxicity in patients treated with (177)Lu-octreotate was low. No (sub)acute grade 3 or 4 renal toxicity occurred and none of the patients had an annual decrease in renal function of >20 %. No risk factors for renal toxicity could be identified. PMC7902029 10.3389/fimmu.2020.620348 Alzheimer's disease (AD) is the leading cause of dementia worldwide giving rise to devastating forms of cognitive decline, which impacts patients' lives and that of their proxies. Pathologically, AD is characterized by extracellular amyloid deposition, neurofibrillary tangles and chronic neuroinflammation. Gijs Kooij Dept. Molecular Cell Biology & Immunology Amsterdam Neuroscience & MS center Amsterdam; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. Gijs Kooij. DR. Assistant Professor, AII - Inflammatory diseases Assistant Professor, Amsterdam Neuroscience - Neuroinfection & -inflammation Assistant Professor, Molecular cell biology and Immunology. PI. 2005 2023.
Coffee medium Kooij
Introduction on peptide receptor radionuclide imaging and therapy Regulatory peptide receptors, such as somatostatin receptors, cholecystokinin (CCK) receptors, glucagon-like peptide-1 (GLP-1) receptors and gastrin-releasing peptide (GRP) receptors, are overexpressed in numerous human cancers. European Journal of Nuclear Medicine and Molecular Imaging. Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al Radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr 3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754-62.
Megalin is a multi-scavenger molecule that is essential for proximal tubular reabsorption of many low molecular weight proteins. Despite this, the exact localisation and mechanism have not been fully eludicated.. Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [111 In-DPTA 0. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003; 30:9-15. doi: 10.1007/s00259-002-0982-3. [Google Scholar]
Coffee ellipse large Kooij
Gijs Kooij is a PI (assistant professor) at the Department of Molecular Cell Biology & Immunology as well as the MS center Amsterdam. His main research focus is to understand the natural process to resolve neuro-inflammation in order to provide new perspectives on the pathogenesis of chronic (unresolved) neuro-inflammatory diseases like multiple sclerosis (MS) and to reveal new treatment. PMCID: PMC4731438 DOI: 10.1007/s00259-015-3193-4 Abstract Purpose: In peptide receptor radionuclide therapy (PRRT), the bone marrow (BM) is one of the dose-limiting organs. The accepted dose limit for BM is 2 Gy, adopted from (131)I treatment.
